TickerFacts.

Arvinas, Inc. (ARVN): Total Assets

Annual figures by period end, from SEC filings.

$717.90M
As of 2025-12-31
$675.10M
As of 2026-06-30
-17.3%
3-year compound annual growth
0.0%
5-year compound annual growth
$1.58B2017-12-31: $66.85M2018-12-31: $199.28M2019-12-31: $301.64M2020-12-31: $717.40M2021-12-31: $1.58B2022-12-31: $1.27B2023-12-31: $1.30B2024-12-31: $1.09B2025-12-31: $717.90M$717.90M
2017-12-31 Total Assets (USD) 2025-12-31
Period endedTotal AssetsChange YoYSource filing
2025-12-31$717.90M-34.2%2026-02-24, Balance as of period end
2024-12-31$1.09B-16.3%2026-02-24, Balance as of period end
2023-12-31$1.30B+2.8%2025-02-11, Balance as of period end
2022-12-31$1.27B-19.8%2024-02-27, Balance as of period end
2021-12-31$1.58B+120.5%2023-02-23, Balance as of period end
2020-12-31$717.40M+137.8%2022-02-28, Balance as of period end
2019-12-31$301.64M+51.4%2021-03-01, Balance as of period end
2018-12-31$199.28M+198.1%2020-03-16, Balance as of period end
2017-12-31$66.85Mn/a2019-03-26, Balance as of period end

Total Assets at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal AssetsChange YoY
Arvinas, Inc. (ARVN)2025-12-31$717.90M-34.2%
Ligand Pharmaceuticals Inc (LGND)2025-12-31$1.56B+65.7%
Vireo Growth Inc. (VREOF)2025-12-31$817.15M+193.0%
Schrodinger, Inc. (SDGR)2025-12-31$726.16M-11.8%
Harrow, Inc. (HROW)2025-12-31$399.48M+2.7%
Arcus Biosciences, Inc. (RCUS)2025-12-31$1.14B-1.0%
Keros Therapeutics, Inc. (KROS)2025-12-31$338.02M-45.1%
Xeris Biopharma Holdings, Inc. (XERS)2025-12-31$383.53M+18.7%
Akebia Therapeutics, Inc. (AKBA)2025-12-31$376.56M+70.6%

Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗